Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $996.00. The company’s shares closed yesterday ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $997.00. Discover outperforming stocks and ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...